- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04617626
Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire (REACH)
REACH Côte d'Ivoire: Feasibility and Acceptability of Integrating Mass Distribution of Azithromycin to Children 1-11 Months Into a Trachoma Mass Drug Administration Campaign to Reduce Child Mortality
The aim of the study is to gather preliminary evidence on the operational feasibility and acceptability of integrating bi-annual mass drug administration (MDA) of single-dose azithromycin for children ages 1 to 11 months in high child mortality settings in Côte. The cross-sectional study will be carried out in conjunction with a single trachoma MDA in selected villages within one health district. Data on feasibility and acceptability will be collected through three main activities:
- Analyses of existing routine monitoring, process, and adverse drug reaction data from the trachoma MDA platform into which the pilot activities are being integrated
- A cross-sectional, post-MDA coverage survey
- Qualitative data collection among targeting parents or primary caregivers of children ages 1 to 11 months in the pilot districts, and district-level MDA implementers, regarding the proposed azithromycin program.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Purpose: The aim of the study is to gather preliminary evidence on the operational feasibility and acceptability of integrating bi-annual mass drug administration (MDA) of single-dose azithromycin for children ages 1 to 11 months in high child mortality settings in Côte d'Ivoire into the existing trachoma MDA platform to inform large scale implementation.
Design: The cross-sectional study will be carried out in conjunction with a single trachoma MDA in selected villages within one health district. Data on feasibility and acceptability will be collected through three main activities:
- Analyses of existing routine monitoring, process, and adverse drug reaction data from the trachoma MDA platform into which the pilot activities are being integrated
- A cross-sectional, post-MDA coverage survey
- Qualitative data collection among targeting parents or primary caregivers of children ages 1 to 11 months in the pilot districts, and district-level MDA implementers, regarding the proposed azithromycin program.
Population: For expanded use of azithromycin: Infants ages 1 to 5 months who reside in one pilot district in high under-5 years child mortality regions in Côte d'Ivoire (approximately 2,800 to be enrolled).
Post-MDA coverage survey and interviews for acceptability: Parents/primary caregivers of infants aged 1 to 11 months who reside in the two pilot districts will be targeted for the post-MDA coverage survey and in-depth interviews (n=up to 24) to explore acceptability (approximately 275 to be enrolled).
Feasibility and acceptability from implementers' perspectives: Focus group discussions will target community-based drug distributors (CDDs) and in-depth interviews will target CDD supervisors, both to explore operational feasibility. (A maximum of 48 CDDs and 12 CDD supervisors approximately) Pilot Site : Boundiali Health District in Bagoué Region, among the high under-5 child mortality regions in Côte d'Ivoire.
Duration: Planning - 6 months; Training and implementation of the pilot intervention - 3 weeks; Post-MDA research - 1 month; Data analysis and reporting - 2 months.
Objectives: The study is designed to:
- Examine the extent to which activities are carried out as planned (fidelity) during the pilot implementation and the factors that affect the processes and results.
- Estimate coverage of the intervention's target population (1 to 11 month-olds) with azithromycin in pilot districts.
- Assess the level of understanding and acceptability of the strategy among those involved in implementation and among the parents/primary caregivers of children targeted by the intervention.
- Document challenges to implementation and costs of the pilot activity to make recommendations for scale-up.
Endpoints: A final pilot activity report summarizing findings including recommended approaches for scale-up, will be developed after results are shared with the REACH technical working group to inform guidance on scale-up.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Savanes Region
-
Boundiali, Savanes Region, Côte D'Ivoire
- Boundiali Health District
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
For expanded azithromycin access during the MDA
Inclusion Criteria:
- Child aged 1 month (at least 30 days) to less than 6 months at the beginning of the week of the MDA intervention
- Resident in study communities
Exclusion Criteria:
- Children below 3.0 kg
- Appears severely ill at the time of the MDA (per the CDD's assessment)
- Unable to swallow liquid delivered through a needle-less syringe because of physical limitations
- Known allergy to macrolides, including azithromycin, based on the primary caregiver's report of prior adverse reaction to medication likely to be a macrolide
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Azithromycin
All children ages 1 to 5 months in the targeted health district will be offered a single dose of azithromycin suspension dosed at 20 mg per kg of weight in place of the standard tetracycline ointment, during a mass drug administration targeting trachoma prevention and treatment.
All children ages 6 months and older, and all adults already receive the single dose of azithromycin during the MDA event.
For this pilot study, single dose of azithromycin is being extended to include the 1 to 5 month old population as well.
|
Single dose of azithromycin suspension
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of children 1 to 11 months reached with single-dose azithromycin
Time Frame: 1 week
|
The proportion of children 1 to 11 months of age who receive a single dose of azithromycin during the MDA in the target health district.
|
1 week
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1575564
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- Study Protocol
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Child Mortality
-
The Hospital for Sick ChildrenAga Khan University; March of DimesCompletedChild Development | Child Mortality | Child Morbidity | Child BehaviourPakistan
-
FHI 360Ministère de la Santé et de l´Hygiène Publique (Côte d'Ivoire)Recruiting
-
The Hospital for Sick ChildrenAga Khan University; Grand Challenges Canada; March of DimesCompletedMortality | Child Development | Morbidity | Child BehaviourKenya
-
University of California, San FranciscoBill and Melinda Gates Foundation; Programme National de Santé Oculaire, Ministère...RecruitingMortality | Child Health | ImplementationNiger
-
University of California, San FranciscoBill and Melinda Gates Foundation; Centre de Recherche en Sante de Nouna, Burkina...CompletedChild Mortality | Resistance Bacterial | Child Growth | Diversity of MicrobiomeBurkina Faso
-
University of California, San FranciscoBill and Melinda Gates Foundation; Ministry of Health, NigerRecruitingMortality | Child, Only | Resistance BacterialNiger
-
Barcelona Institute for Global HealthBill and Melinda Gates Foundation; University of Sierra Leone; Ministry of Health...RecruitingChild MortalitySierra Leone
-
University of California, San FranciscoBill and Melinda Gates Foundation; Helen Keller International; Centre de Recherche...RecruitingChild MortalityUnited States, Burkina Faso
-
University of California, San FranciscoLondon School of Hygiene and Tropical Medicine; National Institute of Allergy... and other collaboratorsCompletedAccess to Health Care | Under-five Child Mortality
-
Institute of Child HealthUnknown
Clinical Trials on Azithromycin
-
PfizerCompletedTonsillitis | PharyngitisBelgium, India, Germany, United States, France, United Kingdom, Netherlands, Finland, Italy, Norway
-
Washington University School of MedicineCompletedRespiratory Syncytial Virus, BronchiolitisUnited States
-
PfizerCompletedBacterial Infections
-
Sheba Medical CenterUnknown
-
GlaxoSmithKlineCompletedAutoimmune DiseasesUnited Kingdom
-
Thomas Jefferson UniversityChristiana Care Health ServicesCompletedPreterm Premature Rupture of MembraneUnited States
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompletedPostpartum Sepsis | Postpartum Endometritis | Postpartum FeverCameroon
-
Emory UniversityThe Carter CenterSuspended
-
University of Alabama at BirminghamCompletedRespiratory Syncytial VirusUnited States